Form 4: UBS Group AG Reports Changes in Beneficial Ownership of ENDRA Life Sciences Inc.

UBS Group AG, through its subsidiaries, reports the acquisition and disposition of ENDRA Life Sciences Inc. common stock.

Summary

• UBS Group AG filed a Form 4 detailing changes in beneficial ownership of ENDRA Life Sciences Inc. (NDRA) common stock.
• The transactions occurred on August 27 and 28, 2024.
• These transactions were carried out by UBS Securities LLC and UBS Financial Services Inc., wholly-owned subsidiaries of UBS Group AG.
• On August 27, 2024, a series of purchases and sales were executed at prices ranging from $0.502674 to $0.5598 per share.
• On August 28, 2024, further purchases and sales occurred at prices ranging from $0.47 to $0.50742 per share.
• Following these transactions, UBS Group AG, through its subsidiaries, beneficially owns 154,477 shares of NDRA common stock.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions. It doesn't convey any inherent positive or negative sentiment about the company's performance or future prospects.

Industry Context

This filing reflects the ongoing trading activity of a major institutional investor in a publicly traded company. Form 4 filings are standard disclosures required by the SEC to provide transparency regarding insider transactions.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership percentage.
• The filing provides transparency to the market regarding UBS Group AG's trading activity in ENDRA Life Sciences Inc.

Key Dates

Keywords

beneficial ownership, ENDRA Life Sciences Inc., UBS Group AG, NDRA, Form 4, securities transactions, common stock, subsidiaries